Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
Retatrutide
Not assigned in the current dataset.
Setmelanotide
POMC
Both peptides fall into a similar broad context as Metabolic peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while Retatrutide is more of a hormone peptide and Setmelanotide is better described as a neuropeptide. Both appear to work through Receptor agonist, which is one of the main reasons they can look related despite other differences. Retatrutide has a more synthetic analog origin, while Setmelanotide is closer to synthetic design background and their development context also differs, with Retatrutide in Clinical phase 3 while Setmelanotide is approved. Retatrutide takes the form of a peptide conjugate, whereas Setmelanotide is closer to a cyclic peptide, Retatrutide carries lipidation features, while Setmelanotide instead reflects d-amino acid substitution changes; while their sequence patterns also diverge, with Retatrutide showing alpha-helical domain features and Setmelanotide showing protein-mimetic sequence features.